Search Results

Your search for Christine B. Boers-Doets, RN, MSc matches 2 pages

Showing 1 - 2

By Christine B. Boers-Doets, RN, MSc / December 15, 2013

Assessment Tools to Measure Impact of Dermatologic and Mucosal Adverse Eventsa

aEditor’s Note: References to these tools are provided for educational purposes only. Terms of use for these tools may vary and some may be subject to copyright restrictions. Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE) Patient Completed mcAEs Specific Symptom Experience...

symptom management

By Christine B. Boers-Doets, RN, MSc / December 15, 2013

How to Measure the Impact of Dermatologic and Mucosal Adverse Events on Symptom Burden and Quality of Life

Targeted anticancer therapies like epidermal growth factor receptor (EGFR) inhibitors, multitargeted tyrosine kinase inhibitors (mTKIs), and mammalian target of rapamycin (mTOR) inhibitors frequently result in dermatologic adverse events and mucosal adverse events, or, taken together, mucocutaneous ...

Apr

Today In Oncology

Search Results

Your search for Christine B. Boers-Doets, RN, MSc matches 2 pages

Assessment Tools to Measure Impact of Dermatologic and Mucosal Adverse Eventsa

How to Measure the Impact of Dermatologic and Mucosal Adverse Events on Symptom Burden and Quality of Life

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being